PE20181321A1 - COMBINATIONS AND USES AND TREATMENTS RELATED THEREOF - Google Patents
COMBINATIONS AND USES AND TREATMENTS RELATED THEREOFInfo
- Publication number
- PE20181321A1 PE20181321A1 PE2018000182A PE2018000182A PE20181321A1 PE 20181321 A1 PE20181321 A1 PE 20181321A1 PE 2018000182 A PE2018000182 A PE 2018000182A PE 2018000182 A PE2018000182 A PE 2018000182A PE 20181321 A1 PE20181321 A1 PE 20181321A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cancer
- heavy chain
- light chain
- abp
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 3
- 108091000831 antigen binding proteins Proteins 0.000 abstract 3
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 abstract 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se refiere a una combinacion de una proteina de union a antigeno (ABP) que se une a OX40 y un modulador del receptor tipo Toll 4 (TLR4), en donde ABP es un anticuerpo monoclonal humanizado que comprende una CDR1 de cadena pesada SEQ ID NO: 1, una CDR2 de cadena pesada SEQ ID NO: 2 y una CDR3 de cadena pesada SEQ ID NO: 3, una CDR1 de cadena ligera SEQ ID NO: 7, una CDR2 de cadena ligera SEQ ID NO: 8 y una CDR3 de cadena ligera SEQ ID NO: 9. Tambien se refiere a una composicion farmaceutica. Dicha combinacion es util para el tratamiento del cancer tal como cancer de cabeza y cuello, cancer de mama, de pulmon, entre otrosRefers to a combination of an antigen-binding protein (ABP) that binds to OX40 and a modulator of the Toll-like receptor 4 (TLR4), wherein ABP is a humanized monoclonal antibody comprising a heavy chain CDR1 SEQ ID NO : 1, a heavy chain CDR2 SEQ ID NO: 2 and a heavy chain CDR3 SEQ ID NO: 3, a light chain CDR1 SEQ ID NO: 7, a light chain CDR2 SEQ ID NO: 8 and a CDR3 of light chain SEQ ID NO: 9. Also refers to a pharmaceutical composition. This combination is useful for the treatment of cancer such as head and neck cancer, breast cancer, lung cancer, among others.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201828P | 2015-08-06 | 2015-08-06 | |
| US201662300400P | 2016-02-26 | 2016-02-26 | |
| US201662322906P | 2016-04-15 | 2016-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181321A1 true PE20181321A1 (en) | 2018-08-14 |
Family
ID=63519030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000182A PE20181321A1 (en) | 2015-08-06 | 2016-06-03 | COMBINATIONS AND USES AND TREATMENTS RELATED THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| PE (1) | PE20181321A1 (en) |
-
2016
- 2016-06-03 PE PE2018000182A patent/PE20181321A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191208A1 (en) | ANTI-CD73 ANTIBODIES AND USES OF THEM | |
| PE20211284A1 (en) | ANTI-NKG2A ANTIBODIES AND USES OF THEM | |
| CL2022001189A1 (en) | Antibodies to cd40. (application divisional n° 2017003427) | |
| AR087615A1 (en) | BISPECIFIC MOLECULES OF ANTIGEN UNION | |
| PE20141017A1 (en) | CEA ANTIBODIES | |
| PE20190970A1 (en) | ANTI-CD40 ANTIBODIES AND THEIR USES | |
| PE20190737A1 (en) | ANTI-CD27 ANTIBODIES | |
| CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
| PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
| PE20171654A1 (en) | COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY | |
| PE20181049A1 (en) | AGENTS, USES AND METHODS FOR THE TREATMENT OF SINUCLEINOPATHY | |
| MX2019001469A (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule. | |
| PE20180926A1 (en) | ANTIBODIES AGAINST MEMBER 4 OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (OX40) AND ITS USES | |
| PE20170912A1 (en) | ANTIBODY-DRUG CONJUGATES | |
| PE20221580A1 (en) | THERAPEUTIC ANTIBODIES AND THEIR USES | |
| CL2016002547A1 (en) | Antibodies against bispecific her2 | |
| UY36757A (en) | MONOCLONAL ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY | |
| MX2017002230A (en) | ANTI-LAG3 ANTIBODIES AND FRAGMENTS FROM UNION TO ANTIGEN. | |
| PE20170935A1 (en) | ANTI-HER2 AND IMMUNOCONJUGATED ANTIBODIES | |
| EA201890305A1 (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | |
| EA201890443A1 (en) | BISPECIFIC MONOVALENT DIATELS, ABLE TO CONNECT B7-H3 AND CD3 AND THEIR APPLICATION | |
| PE20180499A1 (en) | UNION TO TAU ANTIBODIES | |
| PE20161311A1 (en) | SPECIFIC ANTIBODIES OF THE INSULIN-SIMILAR GROWTH FACTOR 1 RECEPTOR AND USES OF THE SAME. | |
| MX2017000205A (en) | ANTI-TAU HUMANIZED ANTIBODIES. | |
| PE20150002A1 (en) | ANTI-FCRN ANTIBODIES |